Antigen presentation by lung macrophages/dendritic cells (DC) is thought to
be important in obliterative bronchiolitis/bronchiolitis obliterans syndro
me (OB/BOS), which severely limits survival post-lung transplantation. Howe
ver, a recent study found minimal numbers of DC in lung allografts. We look
ed at numbers and phenotype of macrophages/DC in lung allografts using endo
bronchial biopsy (EBB) and transbronchial biopsy (TBB) from 22 lung transpl
ant patients. Biopsies were stained with monoclonal markers of DC (CD1a, RF
D1, and major histocompatibility complex [MHC] Class II), and "suppressor m
acrophages" (RFD1 and RFD7). Dendritic cells were also stained for the cost
imulatory molecules CD80 and CD86. Significantly greater numbers of DC/high
-power field (HPF) were seen in biopsies when we defined DC using dendritic
morphology and Class II MHC expression instead of CD1a expression. Dendrit
ic cell numbers were significantly higher in eight patients with OB/BOS com
pared with 14 stable patients. Fifty percent of DC expressed CD86 and 20% e
xpressed CD80. There was no difference in CD80 or CD86 expression between O
B/BOS patients and stable patients. There was no correlation between DC num
bers and presence or absence of acute rejection (AR), and/or cytomegaloviru
s (CMV) pneumonitis on current or prior biopsies. There were significantly
more MHC Class II DC in EBB compared with TBB. We found minimal staining fo
r lung macrophages capable of suppressing T-cell inflammation. We conclude
that studies of lung allografts may underestimate DC numbers if relying on
CD1a as the sole marker of DC. DC are increased in patients with OB/BOS com
pared with stable patients. EBB may be more important than TBB in looking f
or inflammatory changes of OB. DC expressing costimulatory molecules are pr
esent in lung allografts, and costimulatory pathway blockade may be useful
in human lung allografts. Also, the absence of "suppressor" macrophages may
increase susceptibility of human lung allografts to the rejection process.